341 related articles for article (PubMed ID: 2713554)
1. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of multiple myeloma].
Golenkov AK
Sov Med; 1991; (3):43-6. PubMed ID: 1882290
[No Abstract] [Full Text] [Related]
3. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
4. [Plasmocytic pleural effusion disclosing multiple myeloma].
Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
6. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
7. [Pneumonia caused by Salmonella in a patient with myeloma].
Fernández P; Roldán V; García MC; Gil MT; Rivas C
Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
[No Abstract] [Full Text] [Related]
8. [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
Attal M; Harousseau JL
Bull Cancer; 2001 Sep; 88(9):888-92. PubMed ID: 11604362
[TBL] [Abstract][Full Text] [Related]
9. [Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].
Martín Reyes G; García González I; Alférez MJ; Martínez González JM; Frutos MA
Nefrologia; 2001; 21(2):213-6. PubMed ID: 11464657
[TBL] [Abstract][Full Text] [Related]
10. [Results with the use of the M-2 protocol in plasmacytoma].
Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
[TBL] [Abstract][Full Text] [Related]
11. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
12. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
13. [The influence of verapamil on platelet function in patients with multiple myeloma].
Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M
Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652
[TBL] [Abstract][Full Text] [Related]
14. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for plasma cell myeloma.
Smith L; Alexanian R
CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
[No Abstract] [Full Text] [Related]
16. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
17. Myeloma and related disorders.
Kyle RA; Durie BG; Boccadoro M; Pavlovsky S
Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
[No Abstract] [Full Text] [Related]
18. Expression of BAX in plasma cell dyscrasias.
Renner S; Weisz J; Krajewski S; Krajewska M; Reed JC; Lichtenstein A
Clin Cancer Res; 2000 Jun; 6(6):2371-80. PubMed ID: 10873089
[TBL] [Abstract][Full Text] [Related]
19. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
20. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Lila AM; Mazurov VI; Novik AA
Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
